A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER

Open source

DOI: 10.1002/cncr.32061
Published: 2019 Jul 15
Container: Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.32061,
  title = {A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.},
  author = {Voss MH and Bhatt RS and Vogelzang NJ and Fishman M and Alter RS and Rini BI and Beck JT and Joshi M and Hauke R and Atkins MB and Burgess E and Logan TF and Shaffer D and Parikh R and Moazzam N and Zhang X and Glasser C and Sherman ML and Plimack ER},
  year = {2019},
  journal = {Cancer},
  doi = {10.1002/cncr.32061},
  url = {https://doi.org/10.1002/cncr.32061}
}

RIS

TY  - JOUR
TI  - A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
AU  - Voss MH
AU  - Bhatt RS
AU  - Vogelzang NJ
AU  - Fishman M
AU  - Alter RS
AU  - Rini BI
AU  - Beck JT
AU  - Joshi M
AU  - Hauke R
AU  - Atkins MB
AU  - Burgess E
AU  - Logan TF
AU  - Shaffer D
AU  - Parikh R
AU  - Moazzam N
AU  - Zhang X
AU  - Glasser C
AU  - Sherman ML
AU  - Plimack ER
PY  - 2019
JO  - Cancer
DO  - 10.1002/cncr.32061
UR  - https://doi.org/10.1002/cncr.32061
ER  -

APA

MH, V., RS, B., NJ, V., M, F., RS, A., BI, R., JT, B., M, J., R, H., MB, A., E, B., TF, L., D, S., R, P., N, M., X, Z., C, G., ML, S., & ER, P. (2019). A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.. Cancer. https://doi.org/10.1002/cncr.32061

Source records

pubmed · retrieved 2026-09-27T10:08:53.453Z